CARs differing only in the scFv exhibit disparate capacity to reprogram, revealing modest overflow metabolism of CAR-T cells and metabolic compatibility between cancer cells and CAR-T cells as features of efficacious therapy Nature Metabolism
nature.com/articles/s4225…

T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy jamanetwork.com/journals/jamao…

Love this new review from Nicholas P. Restifo and Luca Gattinoni on engineering synthetic T cell states for T cell based immunotherapies.

rupress.org/jem/article/22…

🚨Fantastic pair of papers in nature today from Evan Weber, Mackall Lab and the Darcy lab Peter Mac Cancer Centre on enforcing stem-like molecular programs in therapeutic T cells through overexpression of #FOXO1 ! 👇
nature.com/articles/s4158…. Children's Hospital Stanford Cancer Institute Parker Institute for Cancer Immunotherapy

Hot off the press! A new article published in Cytotherapy from my group describing the differences in expansion platforms for CAR T-cells.
Check it out 👍
Congrats Hannah W. Song, Ph.D. !!

sciencedirect.com/science/articl…

NEW Magnum Opus to date for CAR T cells in solid tumors - Product fitness, local delivery & pre-existing T cells in tumor impact responses. Congrats to Christine Brown City of Hope team Nature Medicine #immunotherapy #CARTCell #tcellrx nature.com/articles/s4159…

#Tandem24 Uttam Rao presented Sarah Cannon Docs data on use of bendamustine vs Flu/Cy for #CARTcell for #lymphoma - benda associated with efficient lymphodepletion, less neutropenia, similar early PFS and OS

And for those still looking, remember that for there is a TCR for every antigen-MHC complex out there.

Happy Valentine's.

Use of #AI synthetic notes >300,000 clinic conversations, >3,400 PermanenteDoctors catalyst.nejm.org/doi/full/10.10…
—81% Physicians-less screen time during visits and less 'pajama time' work on EHR
—71% Patients-more time spent speaking w/ physicians
—Audit of random 35 notes-high quality

Inosine makes CAR-T cells more stem-like and potent. It redirects their metabolism and reprograms their epigenome and transcriptome. An easy and feasible way to enhance CAR-T cell product potency at clinical scale! ✨💪🏻

REVIEW Nature Immunology Delgoffe Lab
Metabolic waypoints during T cell differentiation
nature.com/articles/s4159…

New #JITC position article and guidelines: Corticosteroid-resistant immune-related adverse events: a systematic review bit.ly/3u0egRp Heinz Läubli Alfred Zippelius Laura Cappelli Jarushka Naidoo

A small #NIH -funded study from @MountSinaiNYCsuggests that the allergy medication dupilumab might help treat some lung cancers when given with immunotherapy, but larger clinical trials are needed to validate the findings. bit.ly/4aiKFTx

Our latest story is out in @CellPressImmunity today!! We show that Stat5 opposes Tox and rewires exhausted CD8s towards more durably protective effector-like states. Shout out to my co-authors, Parker Institute for Cancer Immunotherapy and E. John Wherry
Key take-home messages in the 🧵⬇️
cell.com/immunity/ppt/S…

Immune Dictionary of scRNA-seq profiles of more than 17 immune cell types in response to each of 86 cytokines (>1,400 cytokine–cell type combinations) in mouse lymph nodes in vivo Ang Cui, Ph.D. nature #Hacohen
nature.com/articles/s4158…

Exciting news! Our recent collaboration with UK partners identified a key IL7 SNP 🧬 linked to irAEs across diverse cancer cohorts. Sasha Gusev Stefan Groha Maxine Sun Eddy Saad @[email protected] OncoAlert Nature Medicine

nature.com/articles/s4159…
nature.com/articles/s4159…

We're…

*NEW* CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

'Malignancy was potentially driven by genetic mutations (e.g., TET2, NFKB2, PTPRB and/or JAK3), some of which may have existed in the form of a clone with malignant…

I'm on an email chain with many of the country's leading experts in managing T-cell lymphomas. NO ONE has seen any of these cases. U.S. FDA , do tell...

fda.gov/vaccines-blood…

Very interesting new study on leveraging v-beta targeting to induce durable anti tumor immunity. Some really interesting opportunities and may provoke us re-think what makes T cells 'tumor-specific'. Congrats to the whole team here. science.org/doi/10.1126/sc…

A T cell receptor β chain–directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity | Science TM #verycool science.org/doi/10.1126/sc…